TAAR1 and bile duct papillary neoplasm: Although patients using Tα1 showed a trend toward lower incidence of IPN compared to those using a placebo during hospitalization (15.7% vs 18.1%) and within 90 days after randomization (22.4% vs 25.6%), there was a lack of statistical difference.